Cellares and University of Wisconsin Expand Partnership for Clinical Manufacturing of CRISPR-Edited CAR-T Therapy
Cellares and the University of Wisconsin School of Medicine and Public Health have expanded their partnership to advance clinical manufacturing of the university's CRISPR-edited GD2 CAR-T therapy for solid tumors. The collaboration will utilize Cellares' automated platforms to support regulatory submissions and improve manufacturing processes for pediatric and adult patients. The GD2 CAR-T program targets solid tumors like high-grade gliomas with potential applications for neuroblastoma and melanoma.
Theia Market Signal Identification - AI Assisted
Cellares and the University of Wisconsin School of Medicine and Public Health have expanded their partnership to support clinical manufacturing of the CRISPR-edited GD2 CAR-T therapy for solid tumors. This collaboration builds on a previous partnership established in April 2025.
Cellares will utilize its Cell Shuttle™ and Cell Q™ platforms to provide automated manufacturing and regulatory support for the Investigational New Drug (IND) application to the FDA. The GD2 CAR-T program targets high-grade gliomas and may extend to other GD2+ cancers. The automation aims to reduce manual handling and variability, facilitating the transition from development to clinical trials.
Comments